Breast cancer is one of the most prevalent and reoccurring
cancers and the second most common reason of death in women. Despite advancements in therapeutic strategies for
breast cancer, early
tumor recurrence and
metastasis in patients indicate resistance to chemotherapeutic medicines, such as
paclitaxel due to the abnormal expression of ER and EGF2 in
breast cancer cells. Therefore, the development of alternatives to
paclitaxel is urgently needed to overcome challenges involving drug resistance. An increasing number of studies has revealed
miRNAs as novel natural alternative substances that play a crucial role in regulating several physiological processes and have a close, adverse association with several diseases, including
breast cancer. Due to the therapeutic potential of
miRNA and
paclitaxel in
cancer research, the current review focuses on the differential roles of various
miRNAs in
breast cancer development and treatment.
miRNA delivery to a specific target site, the development of
paclitaxel and
miRNA formulations, and nanotechnological strategies for the delivery of nanopaclitaxel in the management of
breast cancer are discussed. These strategies involve improving the cellular uptake and bioavailability and reducing the toxicity of free
paclitaxel to achieve accumulation
tumor site. Furthermore, a molecular docking study was performed to ascertain the enhanced anticancer activity of the nanoformulation of
ANG1005 and
Abraxane. An in silico analysis revealed that
ANG1005 and
Abraxane nanoformulations have superior and significantly enhanced interactions with the
proteins α-
tubulin and Bcl-2. Therefore,
ANG1005 and
Abraxane may be more suitable in the therapeutic management of
breast cancer than the existing free
paclitaxel.
miRNAs can revert abnormal gene expression to normalcy; since
miRNAs serve as
tumor suppressors. Therefore, restoration of particular
miRNAs levels as a replacement
therapy may be an effective endocrine potential strategy for treating ER positive/ negative breast
cancers.